ArticleScientific reports2025
Risk factors and reasons for romosozumab nonadherence in a case-control study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- 3 months vs 12 months of romosozumab for postmenopausal osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled trial.The lancet. Diabetes & endocrinology · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Risk factors and reasons for romosozumab nonadherence remain unclear. This study compared patients who adhered to romosozumab therapy with those who did not to identify possible risk factors and reasons for treatment nonadherence. This case-control study included all eligible patients diagnosed with osteoporosis who received romosozumab therapy at our hospital between February 2022 and March 2024. The patients were divided into adherence and nonadherent groups. Nonadherence was defined as failure to follow the monthly injection schedule for 12 injections over a one-year period, without transitioning to other antiosteoporotic medications. Relevant data were retrospectively collected from the patients' medical records. Univariate and logistic regression analyses were performed to identify the associations of patient characteristics with romosozumab nonadherence. A subgroup analysis was performed to identify the associations between the reasons for nonadherence and the type of payment for romosozumab therapy. The adherence and nonadherent groups comprised 62 and 69 patients, respectively. Male patients had a 9.03-fold higher risk of nonadherence than did female patients (P = .041). Self-payment for medications was associated with a 2.756-fold higher risk of nonadherence than was receiving a full subsidy (P = .024). The most common reasons for nonadherence were patient-related factors (87.0%, 60 of the 69 patients in the nonadherent group), followed by medicine-related factors (8.7%, 6 patients) and health system-related factors (4.3%, 3 patients). Male sex and self-payment for medications are risk factors for romosozumab nonadherence. Patient-related factors appear to be the most common reasons for nonadherence. These results can aid healthcare providers in implementing appropriate interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.